Document:

Exhibit
10.1

 

ICAGEN,
INC. 

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April , 2017, by and between
Icagen, Inc., a Delaware corporation (the “Company”), and the investors set forth on the signature pages affixed
hereto (each, an “Investor” and, collectively, the “Investors”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to exemptions from registration under the Securities
Act (as defined below), the Company desires to issue and sell to each Investor, and each Investor, severally and not jointly,
desires to purchase from the Company, Units (as defined below) of the Company, as more fully described in this Agreement;

 

WHEREAS,
the Investors wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms
and conditions stated in this Agreement, on a “best efforts” basis up to a maximum of 150 Units, each Unit consisting
of (i)the Company’s 8% Senior Secured Promissory Note in the principal amount of $10,000 due on the earlier of (x) the date
that is thirty (30) days after the Issue Date or (y) the closing of the Company’s next debt financing April , 2017 (the
“Note”) and (ii) a five year warrant to purchase 1,500 shares of Common Stock of the Company, par value $0.001,
(the “Common Stock”) for each $10,000 Note investment (the “Common Stock”) of the Company at an
exercise price of $3.50 per share. (the Note and the Warrants being hereinafter referred to as the “Units”
or “Securities”), upon the terms and conditions set forth in this Agreement; and

 

WHEREAS,
in connection with the Investors’ purchase of the Units, the Investors will be subject to certain restrictions on the
transfer of the Securities, all as more fully set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual terms, conditions and other agreements set forth herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties
hereto hereby agree to the sale and purchase of the Units as set forth herein.

 

1.           Definitions.

 

For
purposes of this Agreement, the terms set forth below shall have the corresponding meanings provided below.

 

“Affiliate”
shall mean, with respect to any specified Person (as defined below), (i) if such Person is an individual, the spouse, heirs, executors,
or legal representatives of such individual, or any trusts for the benefit of such individual or such individual’s spouse
and/or lineal descendants, or (ii) otherwise, another Person that directly, or indirectly through one or more intermediaries,
controls, is controlled by, or is under common control with, the Person specified. As used in this definition, “control”
shall mean the possession, directly or indirectly, of the sole and unilateral power to cause the direction of the management and
policies of a Person, whether through the ownership of voting securities or by contract or other written instrument.

 

“Business
Day” shall mean any day on which banks located in New York City are not required or authorized by law to remain closed.

 

“Closing”
and “Closing Date” as defined in Section 2.2 (c) hereof.

 

“Common
Stock” as defined in the recitals above.

 

“Company
Financial Statements” as defined in Section 4.5(a) hereof.

 

     

     

    

 

“Company’s
Knowledge” means the actual knowledge of the Chief Executive Officer (as defined in Rule 405 under the Securities Act),
or the knowledge of any fact or matter which the Chief Executive Officer would reasonably be expected to become aware of in the
course of performing the duties and responsibilities.

 

“Company
Permits” as defined in Section 4.6 hereof.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“First
Closing” and “First Closing Date” as defined in Section 2.2(a) hereof.

 

“Intellectual
Property Rights” as defined in Section 4.13 hereof.

 

“Liens”
means any mortgage, lien, title claim, assignment, encumbrance, security interest, adverse claim, contract of sale, restriction
on use or transfer or other defect of title of any kind.

 

“Material
Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial
or otherwise), business, or prospects of the Company; (ii) the transactions contemplated hereby or in any of the Transaction Documents;
or (iii) the ability of the Company to perform its obligations under the Transaction Documents (as defined below).

 

“Person”
shall mean an individual, entity, corporation, partnership, association, limited liability company, limited liability partnership,
joint-stock company, trust or unincorporated organization.

 

“Purchase
Price” shall mean up to $10,000.

 

“Regulation
D” as defined in Section 3.7 hereof.

 

“Regulation
S” as defined in Section 6.1(i)(E) hereof.

 

“Rule
144” means Rule 144 promulgated under the Securities Act (or a successor rule).

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“SEC
Documents” as defined in Section 4.5 hereof.

 

“Securities”
as defined in the recitals above.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Subsequent
Closing” and “Subsequent Closing Date” as defined in Section 2.2(b) hereof.

 

“Subsidiaries”
shall mean any corporation or other entity or organization, whether incorporated or unincorporated, in which the Company owns,
directly or indirectly, any equity or other ownership interest or otherwise controls through contract or otherwise.

 

“Transaction
Documents” shall mean this Agreement, the Note, the Security and Pledge Agreement, and the Warrant.

 

“Transfer”
shall mean any sale, transfer, assignment, conveyance, charge, pledge, mortgage, encumbrance, hypothecation, security interest
or other disposition, or to make or effect any of the above.

 

“Units”
as defined in the recitals above.

 

“Warrant”
as defined in the recitals above.

 

    	 	2	 

     

    

 

2.           Sale
and Purchase of Securities.

 

2.1.         Subscription
for Units by Investors. Subject to the terms and conditions of this Agreement, on the Closing Date (as hereinafter defined)
each of the Investors shall severally, and not jointly, purchase, and the Company shall sell and issue to the Investors, the Units,
in the respective amounts set forth on the signature pages attached hereto in exchange for the Purchase Price.

 

2.2          Closings.

 

(a)          First
Closing. Subject to the terms and conditions set forth in this Agreement, the Company shall issue and sell to each Investor,
and each Investor shall, severally and not jointly, purchase from the Company on the First Closing Date, such number of Units
set forth on the signature pages attached hereto, which will be reflected opposite such Investor’s name on Exhibit A-1
(the “First Closing”). The date of the First Closing is hereinafter referred to as the “First
Closing Date.”

 

(b)         Subsequent
Closing(s). The Company agrees to issue and sell to each Investor listed on the Subsequent Closing Schedule of Investors,
and each such Investor agrees, severally and not jointly, to purchase from the Company on such Subsequent Closing Date such number
of Units set forth on the signature pages attached hereto, which will be reflected opposite such Investor’s name on Exhibit
A-2 (a “Subsequent Closing”). There may be more than one Subsequent Closing; provided, however,
that the final Subsequent Closing shall take place within the time periods determined by the Company. The date of any Subsequent
Closing is hereinafter referred to as a “Subsequent Closing Date.” Notwithstanding the foregoing, the maximum
number of Units to be sold at the First Closing and all Subsequent Closings shall not exceed 150 in the aggregate.

 

(c)          Closing.
The First Closing and any applicable Subsequent Closings are each referred to in this Agreement as a “Closing.”
The First Closing Date and any Subsequent Closing Dates are sometimes referred to herein as a “Closing Date.”
All Closings shall occur at the offices of Gracin & Marlow, LLP., counsel to the Company, at The Chrysler Building, 405 Lexington
Avenue, New York, New York 10174 or remotely via the exchange of documents and signatures.

  

2.3.         Closing
Deliveries. At each Closing, the Company shall deliver to the Investors, against delivery by the Investor of the Purchase
Price (as provided below), a Note, a Warrant and a Security and Pledge Agreement. At each Closing, each Investor shall deliver
or cause to be delivered to the Company the Purchase Price set forth in its counterpart signature page annexed hereto by paying
United States dollars via bank, certified or personal check which has cleared prior to the applicable Closing Date or in immediately
available funds, by wire transfer to the following account:

 

Bank
Name: JPMorgan Chase Bank N.A

Bank
Address: 5950 Glades Road, Boca Raton, Florida, 33431

Routing
number: 267084131

Account
name: Icagen Inc.

Account
number: 672002107

 

3.           Representations,
Warranties and Acknowledgments of the Investors.

 

Each
Investor, severally and not jointly, represents and warrants to the Company solely as to such Investor that:

 

3.1          Authorization.
The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor is a party have been
duly authorized and will each constitute the valid and legally binding obligation of such Investor, enforceable against such Investor
in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability, relating to or affecting creditors’ rights generally.

 

    	 	3	 

     

    

 

3.2          Purchase
Entirely for Own Account. The Securities to be received by such Investor hereunder will be acquired for such Investor’s
own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the
Securities Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same in violation of the Securities Act, without prejudice, however, to such Investor’s right at all times to
sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws.
Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period
of time. Such Investor is not a broker-dealer registered with the SEC under the Exchange Act or an entity engaged in a business
that would require it to be so registered.

 

3.3.         Investment
Experience. Such Investor acknowledges that the purchase of the Securities is a highly speculative investment and that it
can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial
or business matters such that it is capable of evaluating the merits and risks of the investment contemplated hereby.

 

3.4          Disclosure
of Information. Such Investor has had an opportunity to receive all information related to the Company and the Securities
requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms
and conditions of the offering of the Units. Neither such inquiries nor any other due diligence investigation conducted by such
Investor shall modify, amend or affect such Investor’s right to rely on the Company’s representations and warranties
contained in this Agreement. Such Investor acknowledges that it has received and reviewed the Company’s filings with the
SEC and the Transaction Documents.

 

3.5          Restricted
Securities. Such Investor understands that the Units, and the components thereof, are characterized as “restricted securities”
under the U.S. federal securities laws since they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities
Act only in certain limited circumstances.

 

3.6          Legends.
It is understood that, except as provided below, certificates evidencing the Securities may bear the following or any similar
legend:

 

(a)          “The
securities represented hereby may not be transferred unless (i) such securities have been registered for sale pursuant to the
Securities Act of 1933, as amended; (ii) such securities may be sold pursuant to an available exemption from, or in a transaction
not subject to, the registration requirements of the Securities Act; or (iii) the Company has received an opinion of counsel reasonably
satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933 or qualification
under applicable state securities laws.”

 

(b)          If
required by the authorities of any state in connection with the issuance of sale of the Securities, the legend required by such
state authority.

 

3.7          Accredited
Investor/ Bad Boy Acts. Such Investor, and if an entity, all equity holders of such Investor, is an accredited investor as
defined in Rule 501(a) of Regulation D, as amended, under the Securities Act (“Regulation D”). Such Investor
has not been the subject of any bad actor events under Rule 506 of Regulation D.

 

3.8          No
General Solicitation. Such Investor did not learn of the investment in the Securities as a result of any public advertising
or general solicitation.

 

    	 	4	 

     

    

 

3.9          Brokers
and Finders. No Investor will have, as a result of the transactions contemplated by the Transaction Documents, any valid right,
interest or claim against or upon the Company, any Subsidiary or any other Investor, for any commission, fee or other compensation
pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor.

 

4.           Representations
and Warranties of the Company.

 

The
Company represents, warrants and covenants to the Investors that:

 

4.1.         Organization;
Execution, Delivery and Performance.

 

(a)          The
Company is a corporation or other entity duly organized, validly existing and in good standing under the laws of the jurisdiction
in which it is incorporated or organized, with full power and authority (corporate and other) to own, lease, use and operate its
properties and to carry on its business as and where now owned, leased, used, operated and conducted. The Company is duly qualified
as a foreign corporation to do business and is in good standing in every jurisdiction in which its ownership or use of property
or the nature of the business conducted by it makes such qualification necessary except where the failure to be so qualified or
in good standing would not have a Material Adverse Effect.

 

(b)(i)      The
Company has all requisite corporate power and authority to enter into and perform the Transaction Documents and to consummate
the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof;
(ii) the execution and delivery of the Transaction Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including without limitation, the issuance of the Securities) have been duly authorized by the
Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its stockholders,
is required; (iii) each of the Transaction Documents has been duly executed and delivered by the Company by its authorized representative,
and such authorized representative is a true and official representative with authority to sign each such document and the other
documents or certificates executed in connection herewith and bind the Company accordingly; and (iv) each of the Transaction Documents
constitutes, and upon execution and delivery thereof by the Company will constitute, a legal, valid and binding obligation of
the Company enforceable against the Company in accordance with its terms, except to the extent limited by applicable bankruptcy,
insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights and
general principles of equity that restrict the availability of equitable or legal remedies.

 

4.2.         Securities
Duly Authorized. The Notes to be issued to each such Investor pursuant to this Agreement, when issued and delivered in accordance
with the terms of this Agreement, will be duly and validly issued free from all taxes or Liens with respect to the issue thereof
and shall not be subject to preemptive rights or other similar rights of stockholders of the Company. The Warrants to be issued
to each such Investor, when issued in accordance with the terms of this Agreement, will be legal, valid and binding obligations
of the Company enforceable in accordance with their terms. The shares of Common Stock issuable upon exercise of the Warrants in
accordance with their respective terms will be duly and validly issued and fully paid and non-assessable. Subject to the accuracy
of the representations and warranties of the Investors to this Agreement, the offer and issuance by the Company of the Securities
is exempt from registration under the Securities Act.

 

    	 	5	 

     

    

 

4.3          No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby will not: (i) conflict with or result in a violation of any provision
of the Certificate of Incorporation or By-laws of the Company; or (ii) violate or conflict with, or result in a breach of any
provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or
give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent
license or instrument to which the Company or any of its Subsidiaries is a party, except for possible violations, conflicts or
defaults as would not, individually or in the aggregate, have a Material Adverse Effect; or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations
of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected. Neither the Company
nor any of its Subsidiaries is in default (and no event has occurred which with notice or lapse of time or both could put the
Company or any of its Subsidiaries in default) under, and neither the Company nor any of its Subsidiaries has taken any action
or failed to take any action that would give to others any rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party or by which any property or
assets of the Company or any of its Subsidiaries is bound or affected, or for possible defaults as would not, individually or
in the aggregate, have a Material Adverse Effect. The businesses of the Company and its Subsidiaries are not being conducted in
violation of any law, rule ordinance or regulation of any governmental entity, except for possible violations which would not,
individually or in the aggregate, have a Material Adverse Effect. Except as required under the Securities Act, the Exchange Act,
and any applicable state securities laws, the Company is not required to obtain any consent, authorization or order of, or make
any filing or registration with, any court, governmental agency, regulatory agency, self regulatory organization or stock market
or any third party in order for it to execute, deliver or perform any of its obligations under this Agreement or to issue and
sell the Securities in accordance with the terms hereof. All consents, authorizations, orders, filings and registrations which
the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof.

 

4.4.         Capitalization.
As of April 1, 2017, , the authorized capital stock of the Company consists of (i) 50,000,000 shares of Common Stock, of which
6,393,107 shares are outstanding, 10,000,000 shares of Preferred Stock, of which 400,000 are designated Series A Preferred Stock
and no shares are issued and outstanding, 3,000,000 shares are designated Series B Preferred Stock and no shares are issued and
outstanding, 2,147,641 of the authorized shares are reserved for the issuance of warrants, and 1,453,291 options have been issued
to employees, consultants and directors of Icagen, Inc. . In the Offering contemplated by this Agreement, warrants exercisable
for up to 225,000 shares of Common Stock may be issued to investors. The Company has reserved, and at all times will keep reserved,
a sufficient number of shares for issuance upon the conversion of the Notes and the exercise of the Warrants. Except as described
in the SEC Documents, (i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first
refusal, agreements, understandings, claims or other commitments or rights of any character whatsoever relating to, or securities
or rights convertible into or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements
by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company
or any of its Subsidiaries; (ii) there are no agreements or arrangements under which the Company or any of its Subsidiaries is
obligated to register the sale of any of its or their securities under the Securities Act (except for the registration rights
provisions contained herein and piggyback rights of the Series A Preferred Stock) that will be triggered by the issuance of the
Securities. All of such outstanding shares of capital stock are, or upon issuance will be, duly authorized, validly issued, fully
paid and nonassessable. No shares of capital stock of the Company are subject to preemptive rights or any other similar rights
of the stockholders of the Company or any Lien imposed through the actions or failure to act of the Company.

 

    	 	6	 

     

    

 

4.5.         SEC
Information.

 

(a)          The
Company has filed or furnished all registration statements, prospectuses, reports, schedules, forms, statements and other documents
required to be filed or furnished by it with the SEC pursuant to the requirements of the Securities Act or the Exchange Act (all
of the foregoing and all other documents filed with the SEC prior to the date hereof, being hereinafter referred to herein as
the “SEC Documents”). The SEC Documents have been made available to the Investors via the SEC’s EDGAR
system. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Exchange
Act or the Securities Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder applicable to the
SEC Documents, and none of the SEC Documents, including any financial statements, schedules or exhibits included or incorporated
by reference therein, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to
state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. There are not outstanding any unresolved comments of the staff of the SEC. As of their
respective dates, the financial statements of the Company included in the SEC Documents (“Company Financial Statements”)
complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of
the SEC with respect thereto. The Company Financial Statements have been prepared in accordance with United States generally accepted
accounting principles (“GAAP”), consistently applied, during the periods involved (except (i) as may be otherwise
indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent
they may not include footnotes or may be condensed or summary statements in accordance with GAAP and the applicable rules and
regulations of the SEC) and fairly present in all material respects the consolidated financial position of the Company and its
consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments as permitted by GAAP and the applicable
rules and regulations of the SEC). Except as set forth in the Company Financial Statements, the Company has no liabilities, contingent
or otherwise, other than: (i) liabilities incurred in the ordinary course of business subsequent to September 30, 2016 (the fiscal
period end of the Company’s most recently-filed periodic report) and (ii) obligations under contracts and commitments incurred
in the ordinary course of business and not required under generally accepted accounting principles to be reflected in such financial
statements, which, individually or in the aggregate, are not material to the financial condition or operating results of the Company.

 

(b)          The
shares of Common Stock are not currently traded on any market.

 

4.6          Permits;
Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations, licenses,
permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its
properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”),
and there is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of
the Company Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of
the Company Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. Since September 30, 2016, neither the Company nor any of its Subsidiaries
has received any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices
relating to possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse
Effect.

 

4.7          Litigation.
Except as set forth in the SEC Documents, there is no action, suit, claim, proceeding, inquiry or investigation before or by any
court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any
of its Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their respective businesses, properties
or assets or their officers or directors in their capacity as such, that would have a Material Adverse Effect. The Company is
unaware of any facts or circumstances which might give rise to any of the foregoing. There has not been, and to the Company’s
Knowledge, there is not pending or contemplated, any investigation by the SEC involving the Company, any of its Subsidiaries or
any current or former director or executive officer of the Company or any of its Subsidiaries.

 

    	 	7	 

     

    

 

4.8          No
Material Changes.

 

(a)          Since
September 30, 2016, except as set forth in the SEC Documents, there has not been:

 

(i)          Any
material adverse change in the financial condition, operations or business of the Company from that shown on the Company Financial
Statements, or any material transaction or commitment effected or entered into by the Company outside of the ordinary course of
business;

 

(ii)         Any
effect, change or circumstance which has had, or could reasonably be expected to have, a Material Adverse Effect; or

 

(iii)        Any
incurrence of any material liability outside of the ordinary course of business.

 

4.9          No
General Solicitation. Neither the Company nor any person participating on the Company’s behalf in the transactions contemplated
hereby has conducted any “general solicitation,” as such term is defined in Regulation D promulgated under the Securities
Act, with respect to any of the Securities being offered hereby.

 

4.10        No
Integrated Offering. Neither the Company, nor any of its Affiliates, nor any person acting on its or their behalf, has directly
or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would
require registration under the Securities Act of the issuance of the Securities to the Investors. The issuance of the Securities
to the Investors will not be integrated with any other issuance of the Company’s securities (past, current or future) for
purposes of any stockholder approval provisions applicable to the Company or its securities.

 

4.11        No
Brokers. Except as set forth below, the Company has taken no action which would give rise to any claim by any person for brokerage
commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated hereby.

 

4.12        Form
D; Blue Sky Laws. The Company agrees to file a Form D with respect to the Securities as required under Regulation D within
ten days after the First Closing. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably
determine is necessary to qualify the Securities for sale to the Investors at the applicable Closing pursuant to this Agreement
under applicable securities or “blue sky” laws of the states of the United States (or to obtain an exemption from
such qualification).

 

4.13        Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade
names, service marks, service mark registrations, service names, patents, patent rights, copyrights, original works, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (“Intellectual Property Rights”) necessary to conduct their respective
businesses as now conducted and as presently proposed to be conducted. None of the Company’s or its Subsidiaries’
Intellectual Property Rights have expired, terminated or been abandoned, or are expected to expire, terminate or be abandoned,
within two years from the date of this Agreement. The Company has no knowledge of any infringement by the Company or any of its
Subsidiaries of Intellectual Property Rights of others. Except as set forth in the SEC Documents, there is no claim, action or
proceeding being made or brought, or to the Company’s Knowledge, being threatened, against the Company or any of its Subsidiaries
regarding their Intellectual Property Rights. The Company is not aware of any facts or circumstances which might give rise to
any of the foregoing infringements or claims, actions or proceedings. The Company and each of its Subsidiaries have taken reasonable
security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights, except where
failure to take such measures would not, either individually or in the aggregate, reasonably be expected to result in a Material
Adverse Effect.

 

    	 	8	 

     

    

 

4.14        Tax
Status. Except for occurrences that would not, either individually or in the aggregate, reasonably be expected to result in
a Material Adverse Effect, the Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state
income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject; (ii) has timely
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith; and (iii) has set aside on its books provision
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations
apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the
officers of the Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner
as to qualify as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as
amended.

 

4.15        Shell
Company Status. The Company was never a “shell issuer”, as defined in Rule 144(i)(1).

 

4.16        Investment
Company Act Status. The Company and its subsidiaries are not, and after giving effect to the offering and sale of the Units
will not be, required to register as an “investment company” as such term is defined in the Investment Company Act
of 1940, as amended.

 

5.           Transfer
Restrictions.

 

5.1.         Transfer
or Resale. Each Investor understands that:

 

The
sale or resale of all or any portion of the Securities has not been and is not being registered under the Securities Act or any
applicable state securities laws, and all or any portion of the Securities may not be transferred unless:

 

(1)         the
Securities are sold pursuant to an effective registration statement under the Securities Act;

 

(2)         the
Investor shall have delivered to the Company, at the cost of the Company, a customary opinion of counsel that shall be in form,
substance and scope reasonably acceptable to the Company, to the effect that the Securities to be sold or transferred may be sold
or transferred pursuant to an exemption from such registration;

 

(3)         the
Securities are sold or transferred to an “affiliate” (as defined in Rule 144) of the Investor who agrees to
sell or otherwise transfer the Securities only in accordance with this Section 6.1 and who is an Accredited Investor;

 

(4)         the
Securities are sold pursuant to Rule 144; or

 

(5)         the
Securities are sold pursuant to Regulation S under the Securities Act (or a successor rule) (“Regulation S”);

 

and,
in each case, the Investor shall have delivered to the Company, at the cost of the Company, a customary opinion of counsel, in
form, substance and scope reasonably acceptable to the Company. Notwithstanding the foregoing or anything else contained herein
to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account or other lending
arrangement.

 

    	 	9	 

     

    

 

5.2          Transfer
Agent Instructions. If an Investor provides the Company with a customary opinion of counsel, that shall be in form, substance
and scope reasonably acceptable to the Company, to the effect that a public sale or transfer of such Securities may be made without
registration under the Securities Act and such sale or transfer is effected, the Company shall permit the transfer and promptly
instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations
as specified by such Investor. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable
harm to the Investors, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges
that the remedy at law for a breach of its obligations under this Section 5.2 may be inadequate and agrees, in the event of a
breach or threatened breach by the Company of the provisions of this Section, that the Investors shall be entitled, in addition
to all other available remedies, to an injunction restraining any breach and requiring immediate transfer, without the necessity
of showing economic loss and without any bond or other security being required.

 

6.          Conditions
to Closing of the Investors.

 

The
obligation of each Investor hereunder to purchase the Securities at the Closing is subject to the satisfaction, at or before the
Closing Date, of each of the following conditions, provided that these conditions are for each Investor’s sole benefit and
may be waived by such Investor at any time in its sole discretion by providing the Company with prior written notice thereof:

 

6.1          Representations,
Warranties and Covenants. The representations and warranties of the Company shall be true and correct in all material respects
as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties
that speak as of a specific date, which shall be true and correct in all material respects as of such date) and the Company shall
have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required to be performed,
satisfied or complied with by the Company at or prior to the Closing Date.

 

6.2          Consents.
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the
sale of the Securities.

 

6.3          Delivery
by Company. The Company shall have duly executed and delivered to each Investor each of the other Transaction Documents.

 

6.4          No
Material Adverse Effect. Since the date of first execution of this Agreement, no event or series of events shall have occurred
that reasonably would have or result in a Material Adverse Effect.

 

6.5          No
Prohibition. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any
of the transactions contemplated by the Transaction Documents.

 

6.6          Other
Documents. The Company shall have delivered to such Investor such other documents, instruments or certificates relating to
the transactions contemplated by this Agreement as such Investor or its counsel may reasonably request.

 

7.          Conditions
to Closing of the Company.

 

The
obligations of the Company to effect the transactions contemplated by this Agreement with each Investor are subject to the fulfillment
at or prior to each Closing Date of the conditions listed below.

 

7.1.         Representations
and Warranties. The representations and warranties made by such Investor in Section 3 shall be true and correct in all material
respects at the time of Closing as if made on and as of such date.

 

7.2          Corporate
Proceedings. All corporate and other proceedings required to be undertaken by such Investor in connection with the transactions
contemplated hereby shall have occurred and all documents and instruments incident to such proceedings shall be reasonably satisfactory
in substance and form to the Company.

 

    	 	10	 

     

    

 

7.3          Delivery
by the Investor. The Investor shall have duly executed and delivered to each Investor (a) each of the other Transaction Documents
to be signed by the Investor and (b) a Purchaser Questionnaire and a Purchaser Information Request.

 

8.           Miscellaneous.

 

8.1.         Notices.
All notices, requests, demands and other communications provided in connection with this Agreement shall be in writing and shall
be deemed to have been duly given at the time when hand delivered, delivered by express courier, or sent by facsimile (with receipt
confirmed by the sender’s transmitting device) in accordance with the contact information provided below or such other contact
information as the parties may have duly provided by notice.

 

	The
        Company:

         

        Icagen,
        Inc.

        4222
        Emperor Blvd., Suite 350

        Durham,
        North Carolina 27703

        Telephone:
        (919) 941-5206

        Facsimile:
        (302) 347 1326

        Attention:
        Mark Korb

                           Chief
        Financial Officer
	With
        a copy to:

         

        Gracin
        & Marlow, LLP

        The
        Chrysler Building

        405
        Lexington Avenue, 26th Floor

        New
        York, New York 10174

        Attention:
        Leslie Marlow, Esq.

        Telephone:
        (212) 907-6457

        Facsimile:
        (212) 208-4657

 

The Investors:

 

As per the contact
information provided on the signature pages hereof.

 

8.2          Survival
of Representations and Warranties. Each party hereto covenants and agrees that the representations and warranties of such
party contained in this Agreement shall survive the Closing. Each Investor shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.

 

8.3          Indemnification.

 

(a)          The
Company agrees to indemnify and hold harmless each Investor and its Affiliates and their respective directors, officers, employees
and agents from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable
attorney fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action,
claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to
which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to
be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts
as they are incurred by such Person.

 

(b)          Promptly
after receipt by any Investor (the “Indemnified Person”) of notice of any demand, claim or circumstances which
would or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnity
may be sought pursuant to this Section 8.4, such Indemnified Person shall promptly notify the Company in writing and the Company
shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Person, and
shall assume the payment of all fees and expenses; provided, however, that the failure of any Indemnified Person
so to notify the Company shall not relieve the Company of its obligations hereunder except to the extent that the Company is materially
prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified
Person shall have mutually agreed to the retention of such counsel; or (ii) in the reasonable judgment of counsel to such Indemnified
Person representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests
between them. The Company shall not be liable for any settlement of any proceeding effected without its written consent, which
consent shall not be unreasonably withheld, but if settled with such consent, or if there be a final judgment for the plaintiff,
the Company shall indemnify and hold harmless such Indemnified Person from and against any loss or liability (to the extent stated
above) by reason of such settlement or judgment. Without the prior written consent of the Indemnified Person, which consent shall
not be unreasonably withheld, the Company shall not affect any settlement of any pending or threatened proceeding in respect of
which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder by such Indemnified
Party, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such
proceeding.

 

    	 	11	 

     

    

 

8.4          Entire
Agreement. This Agreement contains the entire agreement between the parties hereto in respect of the subject matter contained
herein and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter
contained herein.

 

8.5          Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns only.

 

8.6          Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.
Neither the Company nor any Investor shall assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other.

 

8.7          Public
Disclosures. The Company shall on or before 8:30 a.m., New York time, within four Business Days after the date of this Agreement,
file a Current Report on Form 8-K describing all the material terms of the transactions contemplated by the Transaction Documents
in the form required by the 1934 Act and attaching all the material Transaction Documents (including, without limitation, this
Agreement (and all schedules to this Agreement) (including all attachments, the “8-K Filing”).

 

8.8          Binding
Effect; Benefits. This Agreement and all the provisions hereof shall be binding upon and inure to the benefit of the parties
hereto and their respective successors and permitted assigns; nothing in this Agreement, expressed or implied, is intended to
confer on any persons other than the parties hereto or their respective successors and permitted assigns, any rights, remedies,
obligations or liabilities under or by reason of this Agreement.

 

8.9          Amendment;
Waivers. All modifications, amendments or waivers to this Agreement shall require the written consent of each of (i) the Company
and (ii) the Investors owning a majority in principal amount of the Notes.

 

8.10       Applicable
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving
effect to the conflict of law provisions thereof, and the parties hereto.

 

8.11        Arbitration. 
Each Investor and the Company agree that they shall resolve all disputes, controversies and differences which may arise between
them, out of or in relation to or in connection with this Agreement, after discussion in good faith attempting to reach an amicable
solution.  Provided that such disputes, controversies and differences remain unsettled after discussion between the parties,
both parties agree that those unsettled matter(s) shall be finally settled by arbitration in New York, New York in accordance
with the latest Rules of the American Arbitration Association. Such arbitration shall be conducted by three arbitrators appointed
as follows: each party will appoint one arbitrator and the appointed arbitrators shall appoint a third arbitrator.  If within
thirty (30) days after confirmation of the last appointed arbitrator, such arbitrators have failed to agree upon a chairman, then
the chairman will be appointed by the American Arbitration Association.  The decision of the tribunal shall be final and
may not be appealed.  The arbitral tribunal may, in its discretion award fees and costs as part of its award. Judgment on
the arbitral award may be entered by any court of competent jurisdiction, including any court that has jurisdiction over either
party or any of their assets. At the request of any party, the arbitration proceeding shall be conducted in the utmost secrecy
subject to a requirement of law to disclose. In such case, all documents, testimony and records shall be received, heard and maintained
by the arbitrators in secrecy, available for inspection only by any party and by their attorneys and experts who shall agree,
in advance and in writing, to receive all such information in secrecy.

 

    	 	12	 

     

    

 

8.12        Further
Assurances. Each party hereto shall do and perform or cause to be done and performed all such further acts and shall execute
and deliver all such other agreements, certificates, instruments and documents as any other party hereto reasonably may request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

8.13        Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which
taken together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be
deemed an original.

 

8.14        Independent
Nature of Investors. The obligations of each Investor under this Agreement or other transaction document are several and not
joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations
of any other Investor under this Agreement or any other transaction document. Each Investor shall be responsible only for its
own representations, warranties, agreements and covenants hereunder. The decision of each Investor to purchase Securities pursuant
to this Agreement has been made by such Investor independently of any other Investor and independently of any information, materials,
statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition
(financial or otherwise) or prospects of the Company which may have been made or given by any other Investor or by any agent or
employee of any other Investor, and no Investor or any of its agents or employees shall have any liability to any other Investor
(or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein
or in any other transaction document, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute
the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the
Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by
this Agreement. Except as otherwise provided in this Agreement or any other transaction document, each Investor shall be entitled
to independently protect and enforce its rights arising out of this Agreement or out of the other transaction documents, and it
shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. Each Investor
has been represented by its own separate legal counsel in connection with the transactions contemplated hereby.

 

8.15        Compensation
of Placement Agent. Each Investor acknowledges that it is aware that the Placement Agent (Taglich Brothers, Inc.) will receive
from the Company, in consideration for its services as financial advisor and placement agent in respect of the transaction contemplated
hereby (a) a commission equal to 6% of the principal amount of Notes sold at each Closing exclusive of Notes issued to the Chairman
of the Board, payable in cash; and (b) five year warrants to purchase such number of shares of the Company’s common stock
equal 2,500 shares of common stock for each $100,000 in principal amount of Notes sold at each Closing, exercisable at an exercise
price of $3.50 per share, exclusive of Notes issued to the Chairman of the Board (the “Placement Agent Warrant”).
The Placement Agent shall have the right to exchange the Placement Agent Warrants for a like number of Warrants issued to the
lender in the Company’s next debt financing.

  

8.16        Warrant
Exchange. Each Investor shall have the right, at any time within the ten (10) day period after its receipt of notice from
the Company of the consummation of its next debt offering, by the provision of a written notice to the Company, to exchange the
Warrant for a like number of warrants issued to the lender in the Company’s next debt financing.

 

[Signature
Page to Follow]

 

    	 	13	 

     

    

 

IN
WITNESS WHEREOF, the undersigned Investors and the Company have caused this Securities Purchase Agreement to be duly executed
as of the date first above written.

 

	ICAGEN,
    INC.	 
	 	 	 
	By:	 	 
	Name:
    	Richard
    Cunningham	 
	Title:  	President
    and Chief Executive Officer	 

 

INVESTORS:

 

The
Investors executing the Signature Page in the form attached hereto as Annex 1 and Purchaser Questionnaire the form attached
hereto as Annex 2 and delivering the same to the Company or its agents shall be deemed to have executed this Agreement
and agreed to the terms hereof.

 

    	 	14	 

     

    

 

ANNEX
1

 

Securities Purchase Agreement

Investor Counterpart Signature Page

 

The
undersigned, desiring to: (i) enter into this Securities Purchase Agreement dated as of April ,2017 (the “Agreement”),
with the undersigned, Icagen, Inc., a Delaware corporation (the “Company”), in or substantially in the form
furnished to the undersigned and (ii) purchase the Units as set forth below, hereby agrees to purchase such Units from the Company
as of the Closing and further agrees to join the Agreement as a party thereto, with all the rights and privileges appertaining
thereto, and to be bound in all respects by the terms and conditions thereof. The undersigned specifically acknowledges having
read the representations in the Agreement section entitled “Representations, Warranties and Acknowledgments of the Investors,”
and hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as an Investor.

 

	All
    Investors: 	 	 	Name
    of Investor:
	 	 	 	 
	Address:	 	 	If
    an entity: 
	 	 	 	 
	 	 	 	Print
    Name of Entity:
	 	 	 
	 	 	 	 
	 	 	 	By:	 
	 	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 	 
	Telephone No.:	 	 	If
    an individual:
	 	 	 	 	 
	 	 	 	Print Name:	 
	Facsimile
    No.:	 	 	 	 
	 	 	 	Signature:	 
	 	 	 	 	 
	Email Address:	 	 	If
    joint individuals:
	 	 	 	 	 
	 	 	 	Print Name:	 
	 	 	 	 	 
	 	 	 	Signature:	 

 

The Investor hereby
elects to purchase ____________ Units (to be completed by Investor) at a purchase price of $10,000 per Unit under the Securities
Purchase Agreement at a total Purchase Price of $__________ (to be completed by Investor).

 

    	 	A-1-1	 

     

    

 

Annex
2

 

CONFIDENTIAL
PURCHASER QUESTIONNAIRE

 

THIS
QUESTIONNAIRE MUST BE ANSWERED FULLY AND RETURNED ALONG WITH YOUR COMPLETED SUBSCRIPTION AGREEMENT IN CONNECTION WITH YOUR PROSPECTIVE
PURCHASE OF UNITS FROM ICAGEN, INC. (THE “COMPANY”).

 

THE
INFORMATION SUPPLIED IN THIS QUESTIONNAIRE WILL BE HELD IN STRICT CONFIDENCE. NO INFORMATION WILL BE DISCLOSED EXCEPT TO THE EXTENT
THAT SUCH DISCLOSURE IS REQUIRED BY LAW OR REGULATION, OTHERWISE DEMANDED BY PROPER LEGAL PROCESS OR IN LITIGATION INVOLVING THE
COMPANY AND ITS CONTROLLING PERSONS.

 

Capitalized
terms used herein without definition shall have the respective meanings given such terms as set forth in the Subscription Agreement
between Icagen, Inc. and the subscriber signatory thereto (the “Subscription Agreement”).

 

(1)       The
undersigned represents and warrants that he, she or it comes within at least one category marked below, and that for any category
marked, he, she or it has truthfully set forth, where applicable, the factual basis or reason the undersigned comes within that
category. The undersigned agrees to furnish any additional information which the Company deems necessary in order to verify the
answers set forth below.

 

	Category A      	The undersigned
    is an individual (not a partnership, corporation, etc.) whose individual net worth, or joint net worth with his or her spouse,
    presently exceeds $1,000,000.

 

Explanation.
In calculating net worth you may include equity in personal property and may include real estate, provided, however, you cannot
include your principal residence), cash, short-term investments, stock and securities. Equity in personal property and real estate
should be based on the fair market value of such property less debt secured by such property.

 

	Category B      	The undersigned
    is an individual (not a partnership, corporation, etc.) who had an income in excess of $200,000 in each of the two most recent
    years, or joint income with his or her spouse in excess of $300,000 in each of those years (in each case including foreign
    income, tax exempt income and full amount of capital gains and losses but excluding any income of other family members and
    any unrealized capital appreciation) and has a reasonable expectation of reaching the same income level in the current year.

 

	Category C      	The undersigned
    is a director or executive officer of the Company which is issuing and selling the Shares.

 

    	 	A-2-1	 

     

    

 

	Category D      	The undersigned
    is a bank, as defined in Section 3(a)(2) of the Securities Act of 1933, as amended (the “Act”); a savings
    and loan association or other institution as defined in Section 3(a)(5)(A) of the Act, whether acting in its individual
    or fiduciary capacity; any insurance company as defined in Section 2(13) of the Act; any investment company registered
    under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act;
    any Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d)
    of the Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions,
    or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan
    has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security
    Act of 1974 if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is
    either a bank, savings and loan association, insurance company, or registered investment advisor, or if the employee benefit
    plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons
    that are accredited investors. (describe entity)
	 	 
	 	 
	 	 

 

	Category E      	The undersigned
    is a private business development company as defined in section 202(a) (22) of the Investment Advisors Act of 1940. (describe
    entity)
	 	 
	 	 
	 	 

 

	Category F      	The undersigned
    is either a corporation, partnership, Massachusetts business trust, or non-profit organization within the meaning of Section 501(c)(3)
    of the Internal Revenue Code, in each case not formed for the specific purpose of acquiring the Shares and with total assets
    in excess of $5,000,000. (describe entity)
	 	 
	 	 
	 	 

 

	Category G      	The undersigned
    is a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Shares, where the
    purchase is directed by a “sophisticated investor” as defined in Regulation 506(b)(2)(ii) under the Act.
	 	 
	 	 
	 	 

 

	Category H      	The undersigned
    is an entity (other than a trust) in which all of the equity owners are “accredited investors” within one or more
    of the above categories. If relying upon this Category alone, each equity owner must complete a separate copy of this Purchaser
    Questionnaire. (describe entity)
	 	 
	 	 
	 	 

 

The
undersigned agrees that the undersigned will notify the Company at any time on or prior to the applicable closing in the event
that the representations and warranties in this Purchaser Questionnaire shall cease to be true, accurate and complete.

 

    	 	A-2-2	 

     

    

 

(2)         Suitability
(please answer each question)

 

		(a)	For
                                         an individual, please describe your current employment, including the company by which
                                         you are employed and its principal business:
	 	 
	 	 
	 	 

 

		(b)	For
                                         an individual, please describe any college or graduate degrees held by you:
	 	 
	 	 
	 	 

 

	 	(c)	For all subscribers, please list types of prior
    investments:
	 	 
	 	 
	 	 

 

		(d)	For
                                         all subscribers, please state whether you have you participated in other private placements
                                         before:

 

Yes
☐                                             No ☐

 

		(e)	If
                                         your answer to question (d) above was “YES”, please indicate frequency of
                                         such prior participation in private placements of:

 

	 	 	Public

                                         Companies
	 	Private

                                         Companies

	 	Frequently	 	 	 
	 	Occasionally	 	 	 
	 	Never	 	 	 

 

		(f)	For
                                         individuals, do you expect your current level of income to significantly decrease in
                                         the foreseeable future?

 

Yes
☐                                             No ☐

 

		(g)	For
                                         trust, corporate, partnership and other institutional subscribers, do you expect your
                                         total assets to significantly decrease in the foreseeable future?

 

Yes
☐                                             No ☐ 

 

		(h)	For
                                         all subscribers, do you have any other investments or contingent liabilities which you
                                         reasonably anticipate could cause you to need sudden cash requirements in excess of cash
                                         readily available to you?

 

Yes
☐                                             No ☐

 

		(i)	For
                                         all subscribers, are you familiar with the risk aspects and the non-liquidity of investments
                                         such as the Shares for which you seek to purchase?

 

Yes
☐                                             No ☐

 

    	 	A-2-3	 

     

    

 

		(j)	For
                                         all subscribers, do you understand that there is no guarantee of financial return on
                                         this investment and that you run the risk of losing your entire investment?

 

Yes
☐                                             No ☐

 

(3)         Manner
in which title is to be held: (circle one)

 

(a)       Individual
Ownership

(b)       Community
Property

(c)       Joint
Tenant with Right of Survivorship (both parties must sign)

(d)       Partnership

(e)       Tenants
in Common

(f)        Company

(g)       Trust

(h)       Other

 

(4)         FINRA
Affiliation.

 

Are
you affiliated or associated with an FINRA member firm (please check one):

 

Yes
☐                                            No ☐

 

If
Yes, please describe how you are affiliated/associated:

 

_________________________________________________________

_________________________________________________________

_________________________________________________________

 

*If
subscriber is a Registered Representative with an FINRA member firm, have the following acknowledgment signed by the appropriate
party:

 

The
undersigned FINRA member firm acknowledges receipt of the notice required by the FINRA Conduct Rules.

 

_________________________________

Name
of FINRA Member Firm

 

 

By:
______________________________

Authorized
Officer

 

Date:
____________________________

 

    	 	A-2-4	 

     

    

 

(5)
      For Trust Subscribers

 

A.
Certain trusts generally may not qualify as accredited investors except under special circumstances. Therefore, if you intend
to purchase the Shares of the Company in whole or in part through a trust, please answer each of the following questions.

 

Is
the trustee of the trust a national or state bank that is acting in its fiduciary capacity in making the investment on behalf
of the trust?

 

Yes
☐                                            No ☐

 

Does
this investment in the Company exceed 10% of the trust assets?

 

Yes
☐                                            No ☐

 

B.
If the trust is a revocable trust, please complete Question 1 below. If the trust is an irrevocable trust, please
complete Question 2 below.

 

	 	1.	REVOCABLE TRUSTS

 

Can
the trust be amended or revoked at any time by its grantors:

 

Yes
☐                                            No ☐

 

If
yes, please answer the following questions relating to each grantor (please add sheets if necessary):

 

Grantor
Name: _________________________

 

Net
worth of grantor exceeds $1,000,000 (including spouse, if applicable, real estate (excluding personal residence), automobiles,
cash, short-term investments, stock and securities. Equity in personal property and real estate should be based on the fair market
value of such property less debt secured by such property)?

 

Yes
☐                                            No ☐

 

OR

 

Income
(exclusive of any income attributable to spouse) was in excess of $200,000 for 2014 and 2015 and is reasonably expected to be
in excess of $200,000 for 2016?

 

Yes
☐                                            No ☐

 

OR

 

Income
(including income attributable to spouse) was in excess of $300,000 for 2014 and 2015 and is reasonably expected to be in excess
of $300,000 for 2016?

 

Yes
☐                                            No ☐

 

    	 	A-2-5	 

     

    

 

	 	2.	IRREVOCABLE TRUSTS

 

If
the trust is an irrevocable trust, please answer the following questions:

 

Please
provide the name of each trustee:

 

Trustee
Name: ________________________________________

 

Trustee
Name: ________________________________________

 

Does
the trust have assets greater than $5 million?

 

Yes
☐                                            No ☐

 

Do
you have such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of
an investment in the Company?

 

Yes
☐                                            No ☐

 

Indicate
how often you invest in:

 

Marketable
Securities

 

Often
☐       Occasionally ☐       Seldom ☐       Never
☐       

 

Restricted
Securities

 

Often
☐       Occasionally ☐       Seldom ☐       Never
☐       

 

Venture
Capital Companies

 

Often
☐       Occasionally ☐       Seldom ☐       Never
☐       

 

	 	(6)	Bad Actor Disqualifications Questions

 

If
all responses to the questions set forth below in this section (6) are no, please check here ☐

 

		(A)	Have
                                         you been convicted, within 10 years before a sale in the current offering (or 5 years
                                         in the case of issuers, their predecessors and affiliated issuers), of any felony or
                                         misdemeanor:

 

		(i)	In
                                         connection with the purchase or sale of any security?

 

Yes
☐                                            No ☐

 

		(ii)	Involving
                                         the making of any false filing with the Securities and Exchange Commission?

 

Yes
☐                                            No ☐

 

    	 	A-2-6	 

     

    

 

		(iii)	Arising
                                         out of the conduct of the business of an underwriter, broker, dealer, municipal securities
                                         dealer, investment adviser, or paid solicitor of purchasers of securities?

 

Yes
☐                                            No ☐

 

		(B)	Are
                                         you subject to any order, judgment or decree of any court of competent jurisdiction,
                                         entered within five years before such sale, that, at the time of such sale, retrains
                                         or enjoins such person from engaging ort continuing to engage in any conduct or practice:

 

	 	(i)	In connection with the purchase or sale of any
    security?

 

Yes
☐                                            No ☐

 

		(ii)	Involving
                                         the making of any false filing with the Securities and Exchange Commission?

 

Yes
☐                                            No ☐

 

		(iii)	Arising
                                         out of the conduct of the business of an underwriter, broker, dealer, municipal securities
                                         dealer, investment adviser, or paid solicitor of purchasers of securities?

 

Yes
☐                                            No ☐

 

		(C)	Are
                                         you subject to a final order of a state securities commission (or any agency or officer
                                         of a state performing like functions; a state authority that supervises or examines banks,
                                         savings associations, or credit unions; a state insurance commission (or an agency or
                                         officer of a state performing like functions); an appropriate federal banking agency;
                                         the U. S. Commodity Futures Trading Commission; or the National Credit Union Administration
                                         that:

 

		(i)	At
                                         the time of such sale, bars you from:

 

		●	Association
                                         with an entity regulated by such commission, authority, agency, or officer;

 

	 	●	Engaging in the business of securities, insurance
    or banking; or

 

	 	●	Engaging in savings
    association or credit union activities.

 

Yes
☐                                            No ☐

 

		(ii)	Constitutes
                                         a final order based on a violation of any law or regulation that prohibits fraudulent,
                                         manipulative, or deceptive conduct entered within 10 years before the sale of the contemplated
                                         transaction.

 

Yes
☐                                            No ☐

 

    	 	A-2-7	 

     

    

 

		(D)	Are
                                         you currently subject to an order of the Securities and Exchange Commission entered into
                                         pursuant to section 15(b) or 15B(c) of the Securities Exchange Act of 1934 or Section
                                         203(e) or (f) of the Investment Advisers Act of 1940 which:

 

		(i)	Suspends
                                         or revokes your license as a broker, dealer, municipal securities dealer, or investment
                                         adviser?

 

Yes
☐                                            No ☐

 

	 	(ii)	Places limitations on your activities, functions
    or operations?

 

Yes
☐                                            No ☐

 

		(iii)	Bars
                                         you from being associated with any entity or from participating in the offering of any
                                         penny stock?

 

Yes
☐                                            No ☐

 

		(E)	Are
                                         you subject to any order of the Securities and Exchange Commission entered within 5 years
                                         before such sale that, at the time of such sale, orders you to cease and desist from
                                         committing or causing a violation or future violation of:

 

		(i)	Any
                                         scienter-based (intent/knowledge based) anti-fraud provision of the federal securities
                                         laws, including, without limitation, section 17(a)(1) of the Securities Act of 1933,
                                         section 10(b) of the Securities Exchange Act of 1934, and 240.10b-5, section 15(c)(1)
                                         of the Securities Exchange Act of 1934 and section 206(1) of the Investment Advisers
                                         Act of 1940, or any other related rule or regulation?

 

Yes
☐                                            No ☐

 

		(ii)	Section
                                         5 of the Securities Act of 1933?

 

Yes
☐                                            No ☐

 

		(F)	Are
                                         you suspended from membership in, or suspended or barred from association with a member
                                         of, a registered national securities exchange or a registered national or affiliated
                                         securities association for any act or omission to act constituting conduct inconsistent
                                         with just and equitable principles of trade?

 

Yes
☐                                            No ☐

 

    	 	A-2-8	 

     

    

 

		(G)	Have
                                         you filed (as either a registrant or an issuer), or named as an underwriter in, any registration
                                         statement or Regulation A offering statement filed with the Securities and Exchange Commission
                                         that, within 5 years before such sale, were you the subject of a refusal order, or stop
                                         order, or order suspending the Regulation A exemption, or is, at the time of such sale,
                                         the subject of an investigation or proceeding to determine whether a stop order or suspension
                                         order should be issued?

  

Yes
☐                                            No ☐

 

		(H)	Are
                                         you the subject to an United States Postal Service false representation order within
                                         the last 5 years, or are you, at the time of any sale of the securities offered, subject
                                         to a temporary restraining order or preliminary injunction with respect to conduct alleged
                                         by the United States Postal Service to constitute a scheme or device for obtaining money
                                         or property through the mail by means of false representations.

 

Yes
☐                                            No ☐

 

[Remainder
of page intentionally left blank]

 

    	 	A-2-9	 

     

    

 

The
undersigned has been informed of the significance to the Company of the foregoing representations and answers contained in this
Confidential Purchaser Questionnaire and such representations and answers have been provided with the understanding that the Company
will rely on them.

 

	 	 	 	Individual
	 	 	 	 	 
	Date:	 	 	 
	 	 	 	Name
    of Individual
	 	 	 	(Please
    type or print)
	 	 	 	 	 
	 	 	 	 
	 	 	 	Signature
    of Individual
	 	 	 	 	 
	 	 	 	 
	 	 	 	Name
    of Joint Owner
	 	 	 	(Please
    type or print)
	 	 	 	 	 
	 	 	 	 
	 	 	 	Signature
    (Joint Owner)
	 	 	 	 	 
	 	 	 	Partnership,
    Corporation or
	 	 	 	Other
    Entity
	 	 	 	 	 
	Date:	 	 	 
	 	 	 	Print
    or Type Entity Name
	 	 	 	 	 
	 	 	 	By:	 
	 	 	 	 	 
	 	 	 	Name:	 
	 	 	 	 	Print
    or Type Name
	 	 	 	 	 
	 	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 
	 	 	  	Signature
	 	 	 	 	 
	 	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 
	 	 	  	Signature
    (other authorized signatory)

 

 

A-2-10Exhibit 10.2

 

PLEDGE
AND SECURITY AGREEMENT

 

PLEDGE
AND SECURITY AGREEMENT (this “Agreement”), dated as of April , 2017, made by Icagen, Inc., a Delaware corporation
with an address at 4222 Emperor Boulevard, Suite 350 Research Triangle Park, Durham, North Carolina 27703 (the “Pledgor”),
in favor of the individuals listed on Schedule A annexed hereto (herein, each a “Secured Creditor” and together
the “Secured Creditors”).

 

WHEREAS,
each of the Secured Creditors have made a loan to the Pledgor pursuant to a 8% Senior Secured Promissory Note (the “Notes”);
and

 

WHEREAS,
in order to induce the Secured Creditors to extend the loan evidenced by the Notes, the Pledgor has agreed to execute and deliver
to the Secured Creditors a pledge and security agreement providing for the pledge and grant to the Secured Creditors of a security
interest in the Pledgor’s interest in the collateral identified and defined below.

 

NOW,
THEREFORE, in consideration of the premises and the agreements herein and in order to induce the Secured Creditors to make
the loans evidenced by the Notes, the Pledgor hereby agrees with the Secured Creditors as follows:

 

SECTION
1. Definitions. All terms used in this Agreement which are defined in Article 9 of the Uniform Commercial Code (the “Code”)
currently in effect in the State of New York and which are not otherwise defined herein shall have the same meanings herein as
set forth therein.

 

SECTION
2. Pledge and Grant of Security Interest. (a) As collateral security for all of the Obligations (as defined in Section
3 hereof), the Pledgor hereby pledges, assigns and grants to the Secured Creditors a continuing security interest in (i) all of
the current assets of the Pledgor, as of the date of this Agreement including but not limited to all accounts receivable, property,
equipment, chattel paper, contract rights, including all interests in lawsuit claims, and intellectual property and excluding
the (x) equity of Icagen-T, Inc. and the assets of Icagen-T, Inc. and (y) any equipment that is secured by a purchase money lien
(the “Pledged Collateral”); and (ii) all proceeds of the foregoing.

 

(b)     The Pledgor hereby represents and warrants to the Secured Creditors as follows:

 

(i)      The
Pledged Collateral is not pledged to secure any indebtedness other than the Loan;

 

(ii)      The
execution, delivery, and performance of the Pledgor of this Agreement will not violate any provision of law, any order of any
court or other agency of government, or any agreement or other instrument to which the Pledgor is a party or by which the Pledgor
is bound, or be in conflict with, result in a breach of or constitute (with due notice, lapse of time, or both) a default under
any such agreement or other instrument, or result in the creation or imposition of any lien, charge, or encumbrance of any nature
whatsoever upon any of the property of assets of the Pledgor, except as contemplated by the provisions of this Agreement;

 

(iii)     This
Agreement constitutes the legal, valid and binding obligation of the Pledgor and is enforceable against the Pledgor in accordance
with the terms hereof; and

 

(iv)     The
Pledgor is the legal and beneficial owner of the Pledged Collateral.

 

     

     

    

 

SECTION
3. Security for Obligations. The security interest created hereby in the Pledged Collateral constitutes continuing collateral
security for all of the following obligations, whether now existing or hereafter incurred (the “Obligations”):

 

(a)      the prompt payment by the Pledgor, as and when due and payable, of all amounts owing
by it in respect of the Notes; and

 

(b)      the due performance and observance by the Pledgor of all of its other obligations from
time to time existing under this Agreement.

 

SECTION
4. Covenants as to the Pledged Collateral. So long as any of the Obligations shall remain outstanding, the Pledgor will,
unless the Secured Creditors shall otherwise consent in writing:

 

(a)
     keep adequate records concerning the Pledged Collateral and permit the Secured Creditor
or any agents or representatives thereof at any reasonable time and from time to time to examine and make copies of and abstracts
from such records;

 

(b)
    at any time and from time to time, promptly execute and deliver all further instruments
and documents and take all further action that may be necessary or desirable or that the Secured Creditors may request in order
to (i) perfect and protect the security interest created hereby; (ii) enable the Secured Creditors to exercise and enforce his
rights and remedies hereunder in respect of the Pledged Collateral; or (iii) otherwise effect the purposes of this Agreement;
and

 

(c)
      not create or suffer to exist any lien, security interest or other charge or encumbrance
upon or with respect to any Pledged Collateral except for the security interest created hereby.

 

SECTION
5. Additional Provisions Concerning the Pledged Collateral.

 

(a)     The Pledgor hereby authorizes the Secured Creditors to file, without the signature of
the Pledgor where permitted by law, one or more financing or continuation statements, and amendments thereto, relating to the
Pledged Collateral.

 

SECTION
6. Remedies Upon Default. If any Event of Default under the Notes shall have occurred and be continuing:

 

(a)     The Secured Creditors may, exercise in respect of the Pledged Collateral, in addition
to other rights and remedies provided for herein or otherwise available to them, all of the rights and remedies of a secured party
on default under the Code then in effect in the State of New York, and without limiting the generality of the foregoing and without
notice except as specified below, sell the Pledged Collateral or any part thereof in one or more parcels at public or private
sale at such price or prices and on such other terms as the Secured Creditors may deem commercially reasonable. The Pledgor agrees
that, to the extent notice of sale shall be required by law, at least five (5) days’ notice to the Pledgor of the time and
place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. The
Secured Creditors shall not be obligated to make any sale of Pledged Collateral regardless of notice of sale having been given.
The Secured Creditors may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor,
and such sale may, without further notice, be made at the time and place to which it was so adjourned.

 

    	 	2	 

     

    

 

(b)      All cash proceeds received by the Secured Creditors in respect of any sale of, collection
from, or other realization upon, all or any part of the Pledged Collateral may, in the discretion of the Secured Creditors, be
held by the Secured Creditors as collateral for, and/or then or at any time thereafter applied in whole or in part by the Secured
Creditors against, all or any part of the Obligations pro rata as to the principal amount of the Loan. Any surplus of such
cash or cash proceeds held by the Secured Creditors and remaining after payment in full of all of the Obligations shall be paid
over to the Pledgor or to such person as may be lawfully entitled to receive such surplus.

 

(c)      In the event that the proceeds of any such sale, collection or realization are insufficient
to pay all amounts to which the Secured Creditors is legally entitled, the Pledgor shall remain liable for the deficiency and
the Secured Creditors shall retain all rights to collect on such Obligations provided by applicable law.

 

SECTION
7. Notices, Etc. All notices and other communications provided for hereunder shall be in writing and shall be mailed, faxed
or delivered, if to the Pledgor, to it at the addresses set forth above; and if to the Secured Creditors, to each of them at the
address set forth in Schedule A hereto; or as to any of such parties at such other address as shall be designated by such
parties in a written notice to the other parties hereto complying as to delivery with the terms of this Section 7. All such notices
and other communications shall be effective (i) if mailed, when deposited in the mail, (ii) if faxed, when the facsimile transmission
is acknowledged as received, or (iii) if delivered, upon delivery.

 

SECTION
8. Miscellaneous.

 

(a)      No amendment of any provisions of this Agreement shall be effective unless it is in
writing and signed by the Pledgor and the Secured Creditors holding a majority in principal amount of the Notes, and no waiver
of any provision of this Agreement, and no consent to any departure by the Pledgor, shall be effective unless it is in writing
and signed by the Secured Creditors, and then such waiver or consent shall be effective only in the specific instance and for
the specific purpose for which given.

 

(b)      No failure on the part of the Secured Creditors to exercise, and no delay in exercising,
any right hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any such right preclude any
other or further exercise thereof or the exercise of any other right. The rights and remedies of the Secured Creditors provided
herein are cumulative and are in addition to, and not exclusive of, any rights or remedies provided by law.

 

(c)      Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the
remaining portions hereof or thereof or affecting the validity or enforceability of such provision on any other jurisdiction.

 

(d)     This Agreement shall create a continuing security interest in the Pledged Collateral
and shall (i) remain in full force and effect until the payment in full or release of the Obligations and (ii) be binding on the
Pledgor and its assigns and shall inure, together with all rights and remedies of the Secured Creditors hereunder, to the benefit
of the Secured Creditors and their successors, transferees and assigns.

 

(e)      Upon the satisfaction in full of the Obligations: (i) this Agreement and the security
interest created hereby shall terminate and all rights to the Pledged Collateral shall revert to the Pledgor, and (ii) the Secured
Creditors will, upon the Pledgor’s request at the Pledgor’s expense, (A) return to the Pledgor such of the Pledged
Collateral as shall not have been sold or otherwise disposed of or applied pursuant to the terms hereof and (B) execute and deliver
to the Pledgor such documents as the Pledgor shall reasonably request to evidence such termination.

 

(f)      This Agreement shall be governed by and construed in accordance with the laws of the
State of New York, except as required by mandatory provisions of law and except to the extent that the validity and perfection
or the perfection and the effect of perfection or non-perfection of the security interest created hereby, or remedies hereunder,
in respect of any particular Pledged Collateral are governed by the law of a jurisdiction other than the State of New York. The
parties hereto agree that all actions or proceedings arising in connection with this Agreement shall be tried and litigated exclusively
in the State and Federal courts located in New York. The aforementioned choice of venue is intended by the parties to be mandatory
and not permissive in nature, thereby precluding the possibility of litigation between the parties with respect to or arising
out of this Agreement in any jurisdiction other than that specified in this paragraph. Each party hereby waives any right it may
have to assert the doctrine of forum non conveniens or similar doctrine or to object to venue with respect to any proceeding brought
in accordance with this paragraph, and stipulates that the State and Federal courts located in New York shall have in personam
jurisdiction and venue over each of them for the purpose of litigating any dispute, controversy, or proceeding arising out of
or related to this Agreement. Each party hereby authorizes and accepts service of process sufficient for personal jurisdiction
in any action against it as contemplated by this paragraph by registered or certified mail, return receipt requested, postage
prepaid, to its address for the giving of notices as set forth in this Agreement. Any final judgment rendered against a party
in any action or proceeding shall be conclusive as to the subject of such final judgment and may be enforced in other jurisdictions
in any manner provided by law.

 

    	 	3	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered as of the date first above written.

 

	 	ICAGEN,
    INC.
	 	 	 
	 	By:	
	 	Name:	Richard
    Cunningham
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	SECURED
    CREDITOR

  

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]